Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.32 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.32 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.32 |
| ▸ | INPP5B | P32019 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | TPI1 | P60174 | 1/20 | 0.31 |
| ▸ | ITPR3 | Q14573 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrophosphoric Acid SCHEMBL28647299 | 0.92 | FDPS (0.77) | FDPSBLMTDP1CA4BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL10770702 | 0.88 | FDPS (0.83) | FDPSBLMTDP1CA4BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL8416891 | 0.88 | FDPS (0.83) | FDPSBLMTDP1CA4BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL27805716 | 0.88 | FDPS (0.83) | FDPSBLMTDP1CA4BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL29634664 | 0.88 | — | — | |
| Pyrophosphoric Acid SCHEMBL3654 | 0.88 | — | — | |
| Pyrophosphoric Acid SCHEMBL292348 | 0.88 | FDPS (1.00) | FDPSBLMTDP1CA4BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL8851914 | 0.88 | FDPS (1.00) | FDPSBLMTDP1CA4BTN3A1 | |
| Triphosphate SCHEMBL5324872 | 0.86 | FDPS (0.56) | FDPSBLMTDP1CA4BTN3A1 | |
| Pyrophosphoric Acid SCHEMBL23537746 | 0.84 | FDPS (0.91) | FDPSBLMTDP1CA4BTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845054-B2 | Methods and devices for nucleic acids synthesis | GEN9, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230192750-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2023-06-22 | — | — | US | disclosed |
| US-20230192750-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2023-06-22 | — | — | US | disclosed |
| EP-3947408-B1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2023-06-07 | — | — | EP | disclosed |
| US-11560400-B2 | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds | NuCana plc (GB) | 2023-01-24 | — | — | US | disclosed |
| US-11560400-B2 | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds | NuCana plc (GB) | 2023-01-24 | — | — | US | disclosed |
| US-11560400-B2 | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds | NuCana plc (GB) | 2023-01-24 | — | — | US | disclosed |
| EP-4043471-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | Nucana PLC (GB) | 2022-08-17 | — | — | EP | disclosed |
| EP-4043471-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | Nucana PLC (GB) | 2022-08-17 | — | — | EP | disclosed |
| EP-3947408-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | Nucana PLC (GB) | 2022-02-09 | — | — | EP | disclosed |
| WO-2008027558-A2 | ITERATIVE NUCLEIC ACID ASSEMBLY USING ACTIVATION OF VECTOR-ENCODED TRAITS | CODON DEVICES, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2007136833-A2 | METHODS AND COMPOSITIONS FOR APTAMER PRODUCTION AND USES THEREOF | CODON DEVICES, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136840-A2 | NUCLEIC ACID LIBRARY DESIGN AND ASSEMBLY | CODON DEVICES, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136834-A2 | COMBINED EXTENSION AND LIGATION FOR NUCLEIC ACID ASSEMBLY | CODON DEVICES, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136736-A2 | METHODS FOR NUCLEIC ACID SORTING AND SYNTHESIS | CODON DEVICES, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136835-A2 | METHODS AND CELLS FOR CREATING FUNCTIONAL DIVERSITY AND USES THEREOF | CODON DEVICES, INC (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007123742-A2 | METHODS AND COMPOSITIONS FOR INCREASING THE FIDELITY OF MULTIPLEX NUCLEIC ACID ASSEMBLY | CODON DEVICES, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007120624-A2 | CONCERTED NUCLEIC ACID ASSEMBLY REACTIONS | CODON DEVICES, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007117396-A1 | NUCLEIC ACID ASSEMBLY OPTIMIZATION USING CLAMPED MISMATCH BINDING PROTEINS | CODON DEVICES, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070231805-A1 | Nucleic acid assembly optimization using clamped mismatch binding proteins | CODON DEVICES, INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192750-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NUDT1, TYMP, NTPCR | FDPS 182/4885BLM 1468/4885TDP1 762/4885 |
| US-11560400-B2 | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds | NUDT1, NTPCR, TYMP | FDPS 176/4885BLM 1581/4885TDP1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.